{
    "nct_id": "NCT05262400",
    "official_title": "A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* All Study Parts: Permanent treatment discontinuation from prior CDK 4 and/or CDK2 inhibitor due to treatment related toxicity.\n* Part 2B and 1C: Prior treatment with any CDK 4/6 inhibitor, or SERDs (e.g. fulvestrant), or everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway for advanced disease.\n* Parts 2B and 2C: Prior treatment with any CDK4/6 inhibitor for advanced disease.\n* Parts 2B and 2C: Prior treatment with an investigational endocrine therapy for advanced disease.\n* Part 2C: Prior neoadjuvant or adjuvant treatment with a nonsteroidal aromatase inhibitor AI (ie, anastrozole or letrozole) with disease recurrence while on or within 12 months of completing treatment.\n* Part 2C: Any prior systemic treatment for advanced disease.\n* Prior irradiation to >25% of the bone marrow\n* Current use of drugs which have a risk for QTc prolongation\n* Current use or anticipated need for food or drugs that are known strong CYP3A4/5, strong UGT2B7 or UGT1A9 inhibitors or inducers\n* Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry\n\n  * Participants with any other active malignancy within 3 years prior to enrollment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen's disease\n  * Major surgery within 4 weeks prior to study entry\n  * Radiation therapy within 4 weeks prior to study entry.\n  * Clinically important hypertension\n  * Known or suspected hypersensitivity to PF-07220060, PF-07104091, letrozole, fulvestrant, or goserelin (or equivalent to induce chemical menopause if applicable)\n* Known abnormalities in coagulation. Anticoagulation with subcutaneous heparin or prophylactic doses of anticoagulant are allowed\n* Known active uncontrolled or symptomatic central nervous system (CNS) metastases\n* Active inflammatory GI disease\n* Current use or anticipated need for Proton Pump Inhibitors (PPI) within 14 days prior to first dose of the study intervention\n* Previous high-dose chemotherapy requiring stem cell rescue\n* Participants with active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), and known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness\n* Other protocol specific exclusion criteria may apply",
    "miscellaneous_criteria": "Inclusion Criteria\n\n* Part 1: Breast Cancer (BC)\n* HR+, HER2- BC\n* Refractory HR-positive/HER2-positive BC\n* Part 1: Solid Tumors other than BC\n* Part 2:\n* HR-positive/HER2-negative BC\n* Lesion:\n* Part 1: evaluable lesion (including skin or bone lesion only)\n* Part 2: measurable lesion per RECIST v1.1\n* Prior systemic Treatment\n* Part 1: HR-positive/HER2-negative BC\n* At least 1 line of SOC, including CDK4/6 inhibitor therapy and Endocrine Therapy, for advanced or metastatic disease.\n* Prior chemotherapy in the metastatic setting is allowed.\n* Part 1: HR-positive/HER2-positive BC\n* At least 1 prior treatment of approved HER2 targeting therapy.\n* Part 1: Solid Tumors other than BC\n* Participants with no standard therapy available or for which no local regulatory approved standard therapy is available that would confer significant clinical benefit in the medical judgement of the investigator.\n* Part 2A: At least 1 prior systemic therapy for advanced or metastatic disease, including CDK4/6 inhibitor treatment and ET.\n* Parts 2B: At least 1 prior endocrine therapy for advanced or metastatic disease. Progression during treatment or within 12 months of completion of adjuvant endocrine therapy is acceptable.\n* Part 2B: Up to 1 prior line of chemotherapy for advanced/metastatic disease is allowed.\n* General Inclusion Criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n* Adequate renal, liver, and bone marrow function\n* Resolved acute effects of any prior therapy to baseline severity"
}